Minims Phenylephrinhydrochlorid Bausch + Lomb Ireland Limited (Phenylephrine Hydrochloride)

Phenylephrine Hydrochloride, the active ingredient in Minims Phenylephrinhydrochlorid Bausch + Lomb Ireland Limited, is a sympathomimetic (alpha‑adrenergic agonist) presented as an ophthalmic solution for ocular use. It reduces ocular redness by constricting conjunctival blood vessels and is used in patients with conjunctival hyperemia.

GNH USA supplies Minims Phenylephrinhydrochlorid Bausch + Lomb Ireland Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, eye‑care centres and clinics worldwide.

Phenylephrine Hydrochloride is an ophthalmic decongestant that acts on the conjunctival vasculature to relieve redness.

- Conjunctival hyperemia: reduces visible redness of the eye. - Minor ocular irritation: alleviates redness associated with mild inflammation. - Post‑procedural ocular redness: diminishes redness after minor eye procedures.

Phenylephrine Hydrochloride may cause a range of ocular and systemic reactions.

Common Side Effects: - Transient stinging or burning sensation in the eye. - Temporary blurred vision. - Mild eye irritation or discomfort. - Increased tearing.

Serious or Rare Side Effects: - Severe allergic reaction (angioedema, anaphylaxis). - Elevated intraocular pressure. - Corneal edema. - Persistent ocular pain or severe irritation.

Before using Phenylephrine Hydrochloride eye drops, consider the following precautions.

- Pregnancy: safety not established; use only if benefits outweigh risks. - Breastfeeding: unknown safety; consult a healthcare professional. - Narrow‑angle glaucoma: avoid use as it may exacerbate intra‑ocular pressure. - Contact lens wearers: remove lenses before instillation and wait before reinserting. - Concurrent systemic sympathomimetics: monitor for increased cardiovascular effects. - Store at room temperature: keep in the original container, protect from light and moisture.

Phenylephrine Hydrochloride can interact with other medications; review the following.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of systemic hypertension. - Other ocular vasoconstrictors: additive vasoconstriction may increase adverse effects. - Systemic sympathomimetic agents: may potentiate cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Antihistamine eye drops: may reduce the decongestant effect. - Topical anesthetic drops: increased risk of ocular irritation. - Beta‑blocker eye drops: potential additive impact on intra‑ocular pressure.